|
|
Lung Cancer – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 665 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H1 2012', provides an overview of the Lung Cancer therapeutic pipeline. This report provides information on the therapeutic devel.....
Introduction Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H1 2012', provides an overview of the Lung Cancer therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. 'Lung Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Lung Cancer. - A review of the Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Cancer pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Lung Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Lung Cancer pipeline depth and focus of Lung Cancer therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 Introduction 14 Lung Cancer Overview 15 Therapeutics Development 16 Lung Cancer Therapeutics under Development by Companies 18 Lung Cancer Therapeutics under Investigation by Universities/Institutes 35 Late Stage Products 61 Mid Clinical Stage Products 62 Early Clinical Stage Products 63 Discovery and Pre-Clinical Stage Products 64 Lung Cancer Therapeutics – Products under Development by Companies 65 Lung Cancer Therapeutics – Products under Investigation by Universities/Institutes 99 Companies Involved in Lung Cancer Therapeutics Development 187 Lung Cancer – Therapeutics Assessment 397 Drug Profiles 405 Lung Cancer Therapeutics – Drug Profile Updates 526 Lung Cancer Therapeutics – Discontinued Products 554 Lung Cancer Therapeutics - Dormant Products 572 Lung Cancer – Product Development Milestones 644 Appendix 652 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Lung Cancer, H1 2012 28 Products under Development for Lung Cancer – Comparative Analysis, H1 2012 29 Number of Products under Development by Companies, H1 2012 31 Number of Products under Development by Companies, H1 2012 (Contd..1) 32 Number of Products under Development by Companies, H1 2012 (Contd..2) 33 Number of Products under Development by Companies, H1 2012 (Contd..3) 34 Number of Products under Development by Companies, H1 2012 (Contd..4) 35 Number of Products under Development by Companies, H1 2012 (Contd..5) 36 Number of Products under Development by Companies, H1 2012 (Contd..6) 37 Number of Products under Development by Companies, H1 2012 (Contd..7) 38 Number of Products under Development by Companies, H1 2012 (Contd..8) 39 Number of Products under Development by Companies, H1 2012 (Contd..9) 40 Number of Products under Development by Companies, H1 2012 (Contd..10) 41 Number of Products under Development by Companies, H1 2012 (Contd..11) 42 Number of Products under Development by Companies, H1 2012 (Contd..12) 43 Number of Products under Development by Companies, H1 2012 (Contd..13) 44 Number of Products under Development by Companies, H1 2012 (Contd..14) 45 Number of Products under Development by Companies, H1 2012 (Contd..15) 46 Number of Products under Investigation by Universities/Institutes, H1 2012 48 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 49 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 50 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 51 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 52 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 53 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 54 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 55 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 56 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 57 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 58 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 59 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 60 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 61 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 62 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 63 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 64 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 65 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 66 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 67 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 68 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 69 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 70 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 71 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 72 Comparative Analysis by Late Stage Development, H1 2012 73 Comparative Analysis by Mid Clinical Stage Development, H1 2012 74 Comparative Analysis by Early Clinical Stage Development, H1 2012 75 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 76 Products under Development by Companies, H1 2012 77 Products under Development by Companies, H1 2012 (Contd..1) 78 Products under Development by Companies, H1 2012 (Contd..2) 79 Products under Development by Companies, H1 2012 (Contd..3) 80 Products under Development by Companies, H1 2012 (Contd..4) 81 Products under Development by Companies, H1 2012 (Contd..5) 82 Products under Development by Companies, H1 2012 (Contd..6) 83 Products under Development by Companies, H1 2012 (Contd..7) 84 Products under Development by Companies, H1 2012 (Contd..8) 85 Products under Development by Companies, H1 2012 (Contd..9) 86 Products under Development by Companies, H1 2012 (Contd..10) 87 Products under Development by Companies, H1 2012 (Contd..11) 88 Products under Development by Companies, H1 2012 (Contd..12) 89 Products under Development by Companies, H1 2012 (Contd..13) 90 Products under Development by Companies, H1 2012 (Contd..14) 91 Products under Development by Companies, H1 2012 (Contd..15) 92 Products under Development by Companies, H1 2012 (Contd..16) 93 Products under Development by Companies, H1 2012 (Contd..17) 94 Products under Development by Companies, H1 2012 (Contd..18) 95 Products under Development by Companies, H1 2012 (Contd..19) 96 Products under Development by Companies, H1 2012 (Contd..20) 97 Products under Development by Companies, H1 2012 (Contd..21) 98 Products under Development by Companies, H1 2012 (Contd..22) 99 Products under Development by Companies, H1 2012 (Contd..23) 100 Products under Development by Companies, H1 2012 (Contd..24) 101 Products under Development by Companies, H1 2012 (Contd..25) 102 Products under Development by Companies, H1 2012 (Contd..26) 103 Products under Development by Companies, H1 2012 (Contd..27) 104 Products under Development by Companies, H1 2012 (Contd..28) 105 Products under Development by Companies, H1 2012 (Contd..29) 106 Products under Development by Companies, H1 2012 (Contd..30) 107 Products under Development by Companies, H1 2012 (Contd..31) 108 Products under Development by Companies, H1 2012 (Contd..32) 109 Products under Development by Companies, H1 2012 (Contd..33) 110 Products under Investigation by Universities/Institutes, H1 2012 111 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 112 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 113 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 114 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 115 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 116 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 117 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 118 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 119 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 120 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 121 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 122 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 123 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 124 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 125 Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 126 Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 127 Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 128 Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 129 Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 130 Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 131 Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 132 Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 133 Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 134 Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 135 Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 136 Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 137 Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 138 Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 139 Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 140 Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 141 Products under Investigation by Universities/Institutes, H1 2012 (Contd..31) 142 Products under Investigation by Universities/Institutes, H1 2012 (Contd..32) 143 Products under Investigation by Universities/Institutes, H1 2012 (Contd..33) 144 Products under Investigation by Universities/Institutes, H1 2012 (Contd..34) 145 Products under Investigation by Universities/Institutes, H1 2012 (Contd..35) 146 Products under Investigation by Universities/Institutes, H1 2012 (Contd..36) 147 Products under Investigation by Universities/Institutes, H1 2012 (Contd..37) 148 Products under Investigation by Universities/Institutes, H1 2012 (Contd..38) 149 Products under Investigation by Universities/Institutes, H1 2012 (Contd..39) 150 Products under Investigation by Universities/Institutes, H1 2012 (Contd..40) 151 Products under Investigation by Universities/Institutes, H1 2012 (Contd..41) 152 Products under Investigation by Universities/Institutes, H1 2012 (Contd..42) 153 Products under Investigation by Universities/Institutes, H1 2012 (Contd..43) 154 Products under Investigation by Universities/Institutes, H1 2012 (Contd..44) 155 Products under Investigation by Universities/Institutes, H1 2012 (Contd..45) 156 Products under Investigation by Universities/Institutes, H1 2012 (Contd..46) 157 Products under Investigation by Universities/Institutes, H1 2012 (Contd..47) 158 Products under Investigation by Universities/Institutes, H1 2012 (Contd..48) 159 Products under Investigation by Universities/Institutes, H1 2012 (Contd..49) 160 Products under Investigation by Universities/Institutes, H1 2012 (Contd..50) 161 Products under Investigation by Universities/Institutes, H1 2012 (Contd..51) 162 Products under Investigation by Universities/Institutes, H1 2012 (Contd..52) 163 Products under Investigation by Universities/Institutes, H1 2012 (Contd..53) 164 Products under Investigation by Universities/Institutes, H1 2012 (Contd..54) 165 Products under Investigation by Universities/Institutes, H1 2012 (Contd..55) 166 Products under Investigation by Universities/Institutes, H1 2012 (Contd..56) 167 Products under Investigation by Universities/Institutes, H1 2012 (Contd..57) 168 Products under Investigation by Universities/Institutes, H1 2012 (Contd..58) 169 Products under Investigation by Universities/Institutes, H1 2012 (Contd..59) 170 Products under Investigation by Universities/Institutes, H1 2012 (Contd..60) 171 Products under Investigation by Universities/Institutes, H1 2012 (Contd..61) 172 Products under Investigation by Universities/Institutes, H1 2012 (Contd..62) 173 Products under Investigation by Universities/Institutes, H1 2012 (Contd..63) 174 Products under Investigation by Universities/Institutes, H1 2012 (Contd..64) 175 Products under Investigation by Universities/Institutes, H1 2012 (Contd..65) 176 Products under Investigation by Universities/Institutes, H1 2012 (Contd..66) 177 Products under Investigation by Universities/Institutes, H1 2012 (Contd..67) 178 Products under Investigation by Universities/Institutes, H1 2012 (Contd..68) 179 Products under Investigation by Universities/Institutes, H1 2012 (Contd..69) 180 Products under Investigation by Universities/Institutes, H1 2012 (Contd..70) 181 Products under Investigation by Universities/Institutes, H1 2012 (Contd..71) 182 Products under Investigation by Universities/Institutes, H1 2012 (Contd..72) 183 Products under Investigation by Universities/Institutes, H1 2012 (Contd..73) 184 Products under Investigation by Universities/Institutes, H1 2012 (Contd..74) 185 Products under Investigation by Universities/Institutes, H1 2012 (Contd..75) 186 Products under Investigation by Universities/Institutes, H1 2012 (Contd..76) 187 Products under Investigation by Universities/Institutes, H1 2012 (Contd..77) 188 Products under Investigation by Universities/Institutes, H1 2012 (Contd..78) 189 Products under Investigation by Universities/Institutes, H1 2012 (Contd..79) 190 Products under Investigation by Universities/Institutes, H1 2012 (Contd..80) 191 Products under Investigation by Universities/Institutes, H1 2012 (Contd..81) 192 Products under Investigation by Universities/Institutes, H1 2012 (Contd..82) 193 Products under Investigation by Universities/Institutes, H1 2012 (Contd..83) 194 Products under Investigation by Universities/Institutes, H1 2012 (Contd..84) 195 Products under Investigation by Universities/Institutes, H1 2012 (Contd..85) 196 Products under Investigation by Universities/Institutes, H1 2012 (Contd..86) 197 Products under Investigation by Universities/Institutes, H1 2012 (Contd..87) 198 Bristol-Myers Squibb Company, H1 2012 199 Johnson & Johnson, H1 2012 200 Boehringer Ingelheim GmbH, H1 2012 201 F. Hoffmann-La Roche Ltd., H1 2012 202 Kyowa Hakko Kirin Co., Ltd., H1 2012 203 Abbott Laboratories, H1 2012 204 Biogen Idec Inc., H1 2012 205 Helix BioPharma Corp., H1 2012 206 Amgen Inc., H1 2012 207 Sanofi-Aventis, H1 2012 208 AstraZeneca PLC, H1 2012 209 Eli Lilly and Company, H1 2012 210 Viralytics Ltd., H1 2012 211 GlaxoSmithKline plc, H1 2012 212 Seattle Genetics, Inc., H1 2012 213 Genentech, Inc., H1 2012 214 Antigenics, Inc., H1 2012 215 Isis Pharmaceuticals, Inc., H1 2012 216 Daiichi Sankyo Company, Ltd, H1 2012 217 Merck & Co., Inc., H1 2012 218 Dainippon Sumitomo Pharma Co., Ltd., H1 2012 219 A&G Pharmaceutical, Inc., H1 2012 220 Infinity Pharmaceuticals, Inc., H1 2012 221 Albany Molecular Research, Inc., H1 2012 222 YM BioSciences Inc., H1 2012 223 Light Sciences Oncology, Inc., H1 2012 224 List of Figures Number of Products under Development for Lung Cancer, H1 2012 28 Products under Development for Lung Cancer – Comparative Analysis, H1 2012 29 Products under Development by Companies, H1 2012 30 Products under Investigation by Universities/Institutes, H1 2012 47 Late Stage Products, H1 2012 73 Mid Clinical Stage Products, H1 2012 74 Early Clinical Stage Products, H1 2012 75 Discovery and Pre-Clinical Stage Products, H1 2012 76 Assessment by Monotherapy Products, H1 2012 409 Assessment by Combination Products, H1 2012 410 Assessment by Route of Administration, H1 2012 411 Assessment by Stage and Route of Administration, H1 2012 412 Assessment by Molecule Type, H1 2012 414 Assessment by Stage and Molecule Type, H1 2012 415 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||


